Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy

Helsinn Healthcare

Status

Completed

Conditions

Vomiting

Nausea

Cancer

Treatments

Dietary Supplement: Standardized Ginger extract

Study type

Interventional

Funder types

Industry

Identifiers

NCT01887314

HF01-12-69 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is verify the capability of a standardized Ginger (Zingiber officinale) extract to manage nausea in cancer patients receiving highly emetogenic treatments and standard anti-emetogenic therapy.

Full description

This study is a randomized, double-blind, placebo controlled, multicenter study with two parallel groups of patients.

The study will be conducted in 5 Italian clinical sites and will involve 250 patients receiving at least 2 cycles of highly emetogenic treatments.

Patients will be randomly assigned to Ginger treatment or to its Placebo.

All patients will receive, at each chemotherapy cycle, the standard 5-HT3 receptor antagonist antiemetics plus dexamethasone and NK1 receptor antagonist. This will guarantee to all patients an antiemetic prophylaxis for acute and delayed nausea. No additional treatment is usually foreseen for nausea and this justifies the use of placebo in the control group.

Patients will start the study treatment on the day after chemotherapy cycle and will continue until the day of the following cycle; they will suspend the study treatment on the chemotherapy day and will start again on the next day. The choice not to treat the patients with the study product on the chemotherapy day is intended to avoid any possible interference with antiemetic therapy of the first day and chemotherapy, and to analyze the impact of Ginger in delayed phase without confounding factors in acute phase.

Main efficacy assessment of this study is:

To evaluate the protection from delayed nausea (incidence of no delayed nausea and non-significant delayed nausea);

Other efficacy assessments regarding nausea that will be evaluated are:

To evaluate the severity of delayed nausea;
To evaluate the overall duration of nausea;
To evaluate inter cycle nausea;
To evaluate nausea anticipatory symptoms before the 2nd cycle.

Secondary efficacy assessments of this study are:

To evaluate protection from delayed vomiting (number of emetic episodes in delayed phase);
To evaluate the impact of nausea/vomiting on daily life activities (FLIE30 questionnaire);
To evaluate the use of antiemetic rescue medication;
To evaluate the compliance to the treatment;
To assess overall fatigue (BFI31 questionnaire).

Safety assessments of this study are:

Number and typology of adverse events.

Enrollment

250 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male and Females aged > 18 years.
Naïve to chemotherapy.
Patients planned to receive at least 2 cycles of highly emetogenic treatments with cisplatin in single dose > 50 mg/m2 every 21 or 28 days.
Willing and able to understand and sign informed consent and complete the patient diary.

Exclusion criteria

Presence of brain symptomatic metastases (in case of small, asymptomatic metastases and in absence of steroids treatment, the patient is eligible).
Scheduled to receive or having received in the past 4 weeks radiation treatment to brain, abdomen or pelvis.
Emesis or significant nausea within 24 hours before first chemotherapy cycle.
Known hypersensitivity reaction to Ginger or any components of the product.
Patients with coagulopathies causing potential increase risk of bleeding.
Patients on therapy with oral anticoagulants.
Planned surgery procedures in the period of the study or within 2 weeks after the study conclusion.
History of seizures.
Active use of cannabinoids.
Known current or past drug or alcohol abuse.
Use of other investigational drugs within 30 days before study entry or during the study.
Clinically significant findings on physical exam or presence of known clinically significant disease that would interfere with study evaluation